\
&
Contact us
\
&
Contact us
Published on | 7 months ago
Programmes HealthThe European Medicines Agency (EMA) has made available a new clinical trial map, which is now accessible from the public website of the Clinical Trials Information System (CTIS). The map is designed to provide patients and healthcare professionals with easy access to comprehensive, real-time information about clinical trials conducted in their area, increasing access to clinical research in the European Union. Users can look for ongoing trials by geographic area and medical condition. The first version of the map is provided in English. Additional EU languages will be added in the future.
A recording with a demonstration on how to use all the features is available on the EMA website. More information here.
Background: The creation of the map is an action of the Accelerating Clinical Trials in the European Union (ACT EU) initiative workplan for 2025-2026. CTIS includes a public searchable database for healthcare professionals, patients and citizens to deliver the high level of transparency foreseen by the Clinical Trials Regulation. The authorisation and oversight of clinical trials is the responsibility of EU/EEA Member States while EMA is responsible for maintaining CTIS. The European Commission oversees the implementation of the Clinical Trials Regulation.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
